![Albert Collinson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Albert Collinson
Direktor/Vorstandsmitglied bei
HBM HOLDINGS LIMITED
Vermögen: 17 107 $ am 30.06.2026
Profil
Albert R.
Collinson is currently Independent Non-Executive Director at HBM Holdings Ltd. since 2023, President & Director at IncreVet, Inc., and President at Theracos, Inc. since 2009.
Former positions include Senior Vice President-Business Development at Phylos, Inc., Vice President-Global R&D Licensing at BASF Pharma Ltd., and Chief Business Officer at Melinta Subsidiary Corp.
Education includes an undergraduate degree from the University of Rhode Island in 1980 and a doctorate from Brandeis University in 1987.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 11.05.2026 | 12.850 ( 0 % ) | 17 107 $ | 30.06.2026 |
Aktive Positionen von Albert Collinson
| Unternehmen | Position | Beginn |
|---|---|---|
| HBM HOLDINGS LIMITED | Direktor/Vorstandsmitglied | 13.07.2023 |
Theracos, Inc.
 Theracos, Inc. BiotechnologyHealth Technology Develops novel therapeutics for diseases | Präsident | - |
IncreVet, Inc.
 IncreVet, Inc. Pharmaceuticals: MajorHealth Technology Develops veterinary drugs | Präsident | - |
Ehemalige bekannte Positionen von Albert Collinson
| Unternehmen | Position | Ende |
|---|---|---|
Phylos, Inc.
 Phylos, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biopharmaceutical research and manufacturing services | Corporate Officer/Principal | - |
BASF Pharma Ltd.
 BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Produces excipients and active ingredients | Corporate Officer/Principal | - |
Melinta Subsidiary Corp.
 Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products for the treatment of life-threatening infections | Corporate Officer/Principal | - |
Ausbildung von Albert Collinson
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
96
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Phylos, Inc.
Phylos, Inc. Miscellaneous Commercial ServicesCommercial Services Provides biopharmaceutical research and manufacturing services | Commercial Services |
University of Rhode Island
 University of Rhode Island Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BASF Pharma Ltd.
BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Produces excipients and active ingredients | Health Technology |
Brandeis University
 Brandeis University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Melinta Subsidiary Corp.
Melinta Subsidiary Corp. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products for the treatment of life-threatening infections | Health Technology |
Theracos, Inc.
Theracos, Inc. BiotechnologyHealth Technology Develops novel therapeutics for diseases | Health Technology |
HBM Holdings Ltd.
 HBM Holdings Ltd. Pharmaceuticals: OtherHealth Technology Engages in research and development of therapeutics in the fields of immuno-oncology and immunology diseases | Health Technology |
IncreVet, Inc.
IncreVet, Inc. Pharmaceuticals: MajorHealth Technology Develops veterinary drugs | Health Technology |
Wählen Sie MarketScreener 
